8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” This correspondence comments on the unknown prevalence of permanent alopecia following high-dose docetaxel chemotherapy and highlights the need for further understanding and prevention strategies.
September 2024 in “Current Oncology” This review discusses the common occurrence of docetaxel-induced hair loss in cancer patients, including permanent cases, and highlights current and experimental strategies like scalp cooling, minoxidil, and new clinical trials for managing and preventing this side effect.
68 citations
,
May 2012 in “Annals of Oncology” This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.
2 citations
,
May 2018 in “Australasian Journal of Dermatology” This article is a letter to the editors about a novel observation regarding chemotherapy-induced alopecia and does not include an abstract with new research results.
61 citations
,
April 2009 in “British journal of dermatology/British journal of dermatology, Supplement” This study found that irreversible and severe alopecia can occur following docetaxel or paclitaxel chemotherapy in breast cancer patients.